EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Secondary metabolites of Alternaria alternate appraisal of their SARS-CoV-2 inhibitory and anti-inflammatory potentials

Fatma A Moharram, Reham R Ibrahim, Shahenda Mahgoub, Mohamed S Abdel-Aziz, Ahmed M Said, Hui-Chi Huang, Lo-Yun Chen, Kuei-Hung Lai iD, Nashwa Hashad, Mohamed S Mady iD

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0313616 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Fatma A Moharram und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacognosy, Faculty of Pharmacy, Helwan University, Cairo, Egypt. Hauptthemen laut MEDLINE: SARS-CoV-2, Anti-Inflammatory Agents, Alternaria, Antiviral Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council of Taiwan, China Medical University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study identifies the secondary metabolites from Alternaria alternate and evaluates their ACE-2: Spike RBD (SARS-CoV-2) inhibitory activity confirmed via immunoblotting in human lung microvascular endothelial cells. In addition, their in vitro anti-inflammatory potential was assessed using a cell-based assay in LPS-treated RAW 264.7 macrophage cells. Two novel compounds, altenuline ( 1 ), phthalic acid bis (7’/7’’ pentyloxy) isohexyl ester ( 2 ), along with 1-deoxyrubralactone ( 3 ) alternariol-5- O -methyl ether ( 4 ) and alternariol ( 5 ) were identified. Molecular docking and in vitro studies showed that compounds 2 and 4 were promising to counteract SARS-CoV-2 attachment to human ACE-2. Thus, they are considered promising natural anti-viral agents. SwissADME in silico analysis was conducted to predict the drug-like potential. Immunoblotting analysis confirmed that the tested compounds ( 1–4 ) demonstrated downregulation of ACE-2 expression in the endothelial cells from the lungs with variable degrees. Furthermore, the tested compounds ( 1–4 ) showed promising anti-inflammatory activities through TNF-α: TNFR2 inhibitory activity and their inhibitory effect on the proinflammatory cytokines (TNF-α and IL-6) in LPS-stimulated monocytes. In conclusion, our study, for the first time, provides beneficial experimental confirmation for the efficiency of the A . alternate secondary metabolites for the treatment of COVID-19 as they hinder SARS-CoV-2 infection and lower inflammatory responses initiated by SARS-CoV-2. A . alternate and its metabolites are considered in developing preventative and therapeutic tactics for COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Anti-Inflammatory AgentsAlternariaAntiviral AgentsHumansAnimalsMiceMolecular Docking SimulationAngiotensin-Converting Enzyme 2COVID-19RAW 264.7 CellsSpike Glycoprotein, CoronavirusSecondary MetabolismCOVID-19 Drug TreatmentEndothelial CellsLung

Substanzen

Anti-Inflammatory AgentsAntiviral AgentsAngiotensin-Converting Enzyme 2Spike Glycoprotein, CoronavirusACE2 protein, humanspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Department of Pharmacognosy, Faculty of Pharmacy, Helwan University, Cairo, Egypt.
  • Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Helwan University, Cairo, Egypt.
  • Genetic Engineering and Biotechnology Division, Microbial Chemistry Department, National Research Centre, Giza, Egypt.
  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Helwan University, Cairo, Egypt.
  • School of Chinese Medicine, China Medical University, Taichung, Taiwan.
  • Graduate Institute of Pharmacognosy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.

ORCID-Profile: Kuei-Hung Lai, Mohamed S Mady

Förderung

  • National Science and Technology Council of Taiwan
  • China Medical University Hospital

Zitieren

APA

Moharram, F. A., Ibrahim, R. R., Mahgoub, S., Abdel-Aziz, M. S., Said, A. M., Huang, H. C., Chen, L. Y., Lai, K. H., Hashad, N., & Mady, M. S. (2025). Secondary metabolites of Alternaria alternate appraisal of their SARS-CoV-2 inhibitory and anti-inflammatory potentials. PLOS ONE. https://doi.org/10.1371/journal.pone.0313616

Vancouver

Moharram FA, Ibrahim RR, Mahgoub S, Abdel-Aziz MS, Said AM, Huang HC, et al. Secondary metabolites of Alternaria alternate appraisal of their SARS-CoV-2 inhibitory and anti-inflammatory potentials. PLOS ONE. 2025. doi:10.1371/journal.pone.0313616

BibTeX
@article{Moharram2025,
  author = {Moharram, Fatma A and Ibrahim, Reham R and Mahgoub, Shahenda and Abdel-Aziz, Mohamed S and Said, Ahmed M and Huang, Hui-Chi and Chen, Lo-Yun and Lai, Kuei-Hung and Hashad, Nashwa and Mady, Mohamed S},
  title = {Secondary metabolites of Alternaria alternate appraisal of their SARS-CoV-2 inhibitory and anti-inflammatory potentials},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0313616}
}
Kostenlos starten →